Tolemy Bio raises €1.4M to bring AI control to cell therapy labs

What's the deal? Cambridge-based biotech startup Tolemy Bio has raised €1.4M in pre-seed funding to build Orbit, an AI platform that centralises fragmented cell biology data and helps biopharma teams optimise therapeutic experiments. The round is led by Norrsken EvolveDealroom has a profile for this one. Try Dealroom →, withBig Sur VenturesDealroom has a profile for this one. Try Dealroom →, JME VenturesDealroom has a profile for this one. Try Dealroom →, MasiaDealroom has a profile for this one. Try Dealroom →, and a UK stealth fund also participating.

Why now? Cell-based therapies are increasingly central to modern medicine, but experimental workflows remain manual and data-heavy. Up to 70% of biopharma companies cite AI as their most needed technology investment — yet fewer than 3% of smaller firms consider themselves AI-ready. Orbit aims to close that gap.

What could go wrong? At pre-seed, Tolemy Bio is still early. Building and validating virtual-cell AI models requires large, high-quality datasets — a resource-intensive challenge for a small team. The biopharma sales cycle is notoriously long, and convincing labs to overhaul entrenched workflows is rarely straightforward.

The signal: Tolemy Bio's raise reflects a growing conviction that AI's next frontier in drug development isn't just discovery — it's the messy, manual work of cell biology itself. Founders Alex WardDealroom has a profile for this one. Try Dealroom →and Caelan AndersonDealroom has a profile for this one. Try Dealroom → met at Australian cultivated meat startup Vow, where they saw first-hand how poor data infrastructure slows complex cell-based products. Early adopters including MIT, the University of Cambridge, and Anthony NolanDealroom has a profile for this one. Try Dealroom →suggest real demand. If Orbit delivers, it could become foundational infrastructure for the next generation of cell therapy manufacturing.

A.M.